Related Image: Blackberries, Broccoli Sprouts Battle Cancer |
(Date:7/25/2008)...nsumers tips and encourages them to, ,Speak Up,(T...July 25 /PRNewswire-USNewswire/ -- The Pennsylvani...l Patient Safety Day" which,is a national effort t...pate fully in their healthcare by asking questions...ery or illness., "We understand the important rol...
(Date:7/25/2008)...ing Exclusivity Begins -, CORONA, Calif., July 25... Inc. (NYSE: WPI ), a leading specialty pharmaceu... has commenced commercial,shipment of its Omeprazo...g,strength from its Davie, Florida manufacturing f...s 180 days of marketing exclusivity for being the,...
(Date:7/25/2008)...iance to be presented at Fenway Park ... 25 /PRNewswire/ -- CVS/pharmacy announced today,t... million in just 21 days,through its annual in-sto...the seventh year of the annual fundraising effort ...or ALS research. This year,s fundraiser took,place...
(Date:7/25/2008)... Group of New York will present an educational mee...pecially designed for seniors. The lecture will be...ritts Road, Farmingdale, NY 11735, 1:00 to 2:00 p....freshments will be provided. The phone number for ... Hicksville and Hauppauge, NY (PRWEB) ...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3(Date:7/24/2008)...Newswire/ -- Ortho-McNeil Neurologics, a,division ...ounced today,that the U.S. Food and Drug Administr...TOPAMAX(R) (topiramate), based on studies submitte...nvestigate the use of TOPAMAX,in pediatric patient..., In addition to granting pediatric exclusivity, ...
(Date:7/24/2008)...am Speeds Oncology Patient Accrual, DENVER, July ...nagement,Organization (RMO), has contracted with f...search and site management services for their,clin...t strategy. The new,trials include the following d...oma, Metastatic Breast Cancer, Metastatic Sarcoma,...
(Date:7/23/2008)...tion in July print edition of Clinical ...IS, July 23 /- A Roche Diagnostics-sp...al pro-B-type natriuretic peptide,(NT-proBNP) conf...atification in predicting the risk of cardiovascul... non-steroidal anti-inflammatory drugs of,the COX ...
(Date:7/23/2008)...swire/ -- InCode BioPharmaceutics, Inc.,an emergi...linical test,results demonstrating the utility of ...of the rare chronic blood disorder paroxysmal noct...ill be presented at the XXII,International Complem...2008., The only treatment currently available for...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 1Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 2Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 3Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 4Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 5Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 6Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 7Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 8Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 9Aflac Incorporated Announces First Quarter Results Declares Second Quarter Cash Dividend 17595 10NightHawk Radiology Holdings Inc to Host Conference Call to Discuss First Quarter 2008 Earnings Results 17591 1NightHawk Radiology Holdings Inc to Host Conference Call to Discuss First Quarter 2008 Earnings Results 17591 2AARP Commends Illinois U S Reps for Voting to Protect People in Medicaid 17587 1AARP Commends Illinois U S Reps for Voting to Protect People in Medicaid 17587 2The spring in your step is more than just a good mood 17584 1The spring in your step is more than just a good mood 17584 2... WIRE)--Mar 14, 2007 - ArQule, Inc.,(NASDAQ: ARQL)...ical Oncology (ASCO) has accepted for oral present...1 Dose Escalation Study of,ARQ 197, a Selective In...astatic Solid Tumors) at the 43rd ASCO Annual Meet... will describe findings,from a Phase 1 trial with ...
...SS WIRE)--Mar 19, 2007 - Vyteris Holdings,(Nevada)... a new,phase IV "Open Label" clinical study demons...ve patch for dermal analgesia, provided,better pai...ving,injections of hyaluronic acid during treatmen...., "Treatment can be very painful, requiring multi...
Other Medicine Technology:ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 2ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 3ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO 4New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief 2New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief 3New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief 4New Phase IV Clinical Study Indicates LidoSite Provides,Rheumatology Patients Superior Pain Relief 5... a potent naturally occurring androgen produced fr... 5a-reductase [1]. The concentrations of 5a-reduc...cluding genital skin and hair follicles, and are l...with the nuclear membrane. DHT exerts its biologi...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc.
UROSKOP Access, the dedicated urodiagnostic table with truly unrestricted patient access optimizes nearly all diagnostic and interventional procedures.
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential.
Medicine Products: